Search

A recent report from Harvard Medical School discusses research on ovarian cancer and the potential resistance to bispecific T-cell engager (BiTE) therapy. The study focused on the role of hypoxia in the modulation of MUC16, a protein associated with ovarian cancer, and its impact on resistance to BiTE therapy. The researchers found that hypoxia led to a decrease in MUC16 expression on tumor cells, as well as changes in epithelial-mesenchymal transition (EMT) markers and the upregulation of epidermal growth factor receptor (EGFR). Understanding these mechanisms could provide valuable insights into BiTE therapy resistance in ovarian cancer. [Extracted from the article]

A recent study conducted at Massachusetts General Hospital investigated the association between maintenance hormone therapy and overall survival in patients with low-grade advanced-stage ovarian cancer. The study found that patients who received hormone therapy within six months of diagnosis had a reduced risk of death compared to those who did not receive hormone therapy. This research suggests that maintenance hormone therapy may be beneficial for improving overall survival in patients with low-grade advanced-stage ovarian cancer. [Extracted from the article]